| Name | Title | Contact Details |
|---|
MD Revolution harnesses the power of digital health technology to predict, prevent, and reverse chronic disease – and lower healthcare costs. MD Revolution is a transformational digital health provider that delivers a proven population health management service. Our SaaS solution, RevUp, has revolutionized the approach to behavior change for lifestyle diseases including diabetes, obesity, and heart disease. Participants on RevUp receive actionable feedback based on personal health data gathered from wearables and apps. Predictive analytics drive real-time identification of individuals that will or will not achieve desired health outcomes, thereby allowing clinicians and health coaches to focus on participants who require more intensive coaching. Gamification, social and an incentive points system engages employees in their health and builds camaraderie.
Wright Medical Group N.V. is a global medical device company focused on providing extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients` lifestyles. The company is a recognized leader of surgical solutions for the upper extremity (shoulder, elbow, wrist and hand), lower extremity (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics.
Hyphen is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SH3 is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.